Targeting the cardiohepatic-metabolic axis: GLP-1-based and incretin multi-agonist therapies in MASH.
Metabolic dysfunction-associated steatohepatitis (MASH) has emerged as a leading cause of chronic liver disease worldwide and is increasingly recognized as a systemic metabolic-inflammatory disorder closely linked to cardiovascular risk. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and emerging incretin-based m...